SCHEMBL6292289

SCHEMBL6292289

CCCC1=C(C(=O)OCC)C(c2ccccc2Cl)c2c[nH]nc2N1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TBXA2R P21731 3/20 0.48
ADRA1A P35348 3/20 0.48
SLC6A3 Q01959 3/20 0.48
ADORA3 P0DMS8 3/20 0.48
HTR1A P08908 2/20 0.48
ADRA2A P08913 2/20 0.48
CHRM1 P11229 2/20 0.48
DRD1 P21728 2/20 0.48
SLC6A2 P23975 2/20 0.48
OPRM1 P35372 2/20 0.48
DRD3 P35462 2/20 0.48
KCNH2 Q12809 2/20 0.48
CACNA1C Q13936 2/20 0.48
ABCB11 O95342 2/20 0.48
ABCB1 P08183 2/20 0.48
ADRB3 P13945 2/20 0.48
OPRK1 P41145 2/20 0.48
SCN5A Q14524 2/20 0.48
KCNK2 O95069 1/20 0.48
ADRB2 P07550 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6293386 0.94 TBXA2R (0.46) TBXA2RADRA1ASLC6A3ADORA3HTR1A
SCHEMBL6293510 0.92 CYP2C9 (0.54) TBXA2RADRA1ASLC6A3ADORA3HTR1A
SCHEMBL6292579 0.92 CYP2C9 (0.44) TBXA2RADRA1ASLC6A3ADORA3HTR1A
SCHEMBL6293581 0.92 TBXA2R (0.49) TBXA2RADRA1ASLC6A3ADORA3HTR1A
SCHEMBL6296656 0.91 TBXA2R (0.46) TBXA2RADRA1ASLC6A3ADORA3HTR1A
SCHEMBL6292296 0.90 CYP2C9 (0.43) TBXA2RADRA1ASLC6A3ADORA3HTR1A
SCHEMBL6296991 0.89 NR3C2 (0.45) ADORA3LMNACACNA1DNR3C2KMT2A
SCHEMBL6293708 0.88 CA1 (0.45) ADORA3CACNA1DNR3C2KMT2AKDM4E
SCHEMBL6296533 0.88 NR3C2 (0.44) ADORA3ALDH1A1CACNA1DNR3C2KMT2A
SCHEMBL7441431 0.88 PYGL (0.39) TBXA2RADRA1ASLC6A3ADORA3HTR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6977262-B2 Dihydropyrazolopyridine compounds and pharmaceutical use thereof MITSUBISHI PHARMA CORPORATION (JP) 2005-12-20 US disclosed
US-20040052822-A1 Dihydropyrazolopyridine compounds and pharmaceutical use thereof MITSUBISHI PHARMA CORPORATION (JP) 2004-03-18 US disclosed
EP-1355909-A2 DIHYDROPYRAZOLOPYRIDINE COMPOUNDS AND PHARMACEUTICAL USE THEREOF Mitsubishi Pharma Corporation (JP) 2003-10-29 EP disclosed
WO-2002062795-A9 DIHYDROPYRAZOLOPYRIDINE COMPOUNDS AND PHARMACEUTICAL USE THEREOF MITSUBISHI PHARMA CORP (JP) 2002-10-10 WO disclosed
WO-2002062795-A2 DIHYDROPYRAZOLOPYRIDINE COMPOUNDS AND PHARMACEUTICAL USE THEREOF MITSUBISHI PHARMA CORPORATION (JP) 2002-08-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040052822-A1 Dihydropyrazolopyridine compounds and pharmaceutical use thereof GSK3B, GSK3A, PYGB TBXA2R 3650/4885ADRA1A 1189/4885SLC6A3 560/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.